Melius Research downgraded Ametek (AME) to Hold from Buy with a $192 price target While Melius continues to see Ametek as a core holding, the firm doesn’t have a compelling case for outperformance, the analyst tells investors in a research note. This quarter could see some margin relief from tariffs, but the resolution of tariff uncertainty continues to be delayed, while the Big Beautiful Bill has put a lot of uncertainty into clean tech and healthcare end markets, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AME: